anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients are required to perform the modified TOPS program, composed of 10 sessions focused only on health and wellness contents. Thus, this program does not include contents on problem-solving, executive functions, behavioral strategies and social skills, representing a low cognitively simulating activity. Biweekly Google Meet sessions with a cognitive-behavioral psychotherapist are scheduled, with the aim of monitoring training adherence and discuss the program's contents.
Participants will receive esketamine nasal spray (Dose 1 or Dose 2) twice weekly for 4 weeks (Induction Phase), followed by once a week dose (Dose 1 or Dose 2) for 8 weeks (Maintenance Phase), in conjunction with an oral antidepressant. Clinician-directed cognitive behavioral therapy (CBT) supplemented with the Mindset app will be administered by a clinician following esketamine dosing once the participants is considered ready to engage in therapy, based on the clinician judgement of CBT readiness.
The present invention identified novel epitopes from the insulin B chain which is embodied in methods and means for diagnostics and treatment of type 1 diabetes. The epitopes were found in a peptide comprising a fragment of the human insulin B chain. Using HLA-A2 tetramers having the peptide of the invention cytotoxic T-cells were found in peripheral blood cells samples from healthy individuals. The invention demonstrates that these autoreactive CTL directed against insulin B chain are able to destroy insulin producing beta-cells. Moreover, a significant proportion of cytotoxic T-cells from islet transplant recipients with recurrent autoimmunity and loss of insulin production recognized this peptide or analogue thereof. The peptide has a high affinity for the HLA-A2 allele, in particular HLA-A*0201. Based on the novel epitopes according to the invention, diagnostic and therapeutic methods and medicaments for the prevention or treatment of type 1 diabetes are provided.
This study will investigate the efficacy of G-CSF mobilized mononuclear cell injection of patients with PAD who presented with intermittent claudication. Forty PAD patients who presented with intermittent claudication will be randomized into 2 groups. The control group will be treated by medication and walking exercise 3 times/ week. The experiment group will be injected G-CSF mobilized mononuclear cell ,medication and walking exercise 3 times/ week. Ankle brachial index(ABI), Toe brachial index (TBI) and transcutaneous oxygen measurement will be evaluated at the day of randomization, 1 , 3, 6 and 12 months in the control group and day of randomization, 1 , 3, 6 and 12 months after injection of PB-MNC in the experiment group. Pain free walking distance will be evaluated at the day of randomization, 1 , 3, 6 and 12 months by pedometer.
The present invention discloses new live attenuated strains for oral immunization against cholera that are provided in freeze dried formulations for long term storage and administration to humans. These strains combine the two most important properties of live attenuated cholera vaccine candidates. One such property is being well tolerated by people ingesting them. This was achieved by virtue of mutations already described in the art. The second property is having enhanced environmental safety due to the absence of VGJΦ DNA in their genomes and also due to null mutations in the mshA gene or other spontaneous mutations conducive to the lack of MSHA type IV fimbria on the bacterial surface. This was done envisioning that VGJΦ is a filamentous phage able to recombine with CTXΦ and disseminate the cholera toxin genes. This VGJΦ phage as well as the VGJΦ-CTXΦ recombinants uses the MSHA fibers as receptor. Being devoid of MSHA fimbria the vaccine candidates are protected from acquiring CTXΦ from the recombinant hybrid VGJΦ-CTXΦ. Being devoid of VGJΦ, the vaccine candidates are impaired in the dissemination of CTXΦ, via VGJΦ.
A phospholipase A 2  inhibitor protein designated “Phospholipase Inhibitor from Python” (PIP)—formerly designated “Python Antitoxic Factor” (PAF)—is given by SEQ ID NO:2. The partial amino acid sequence for PIP was initially determined from the native protein purified from the blood serum of a non-venomous snake,  Python reticulatus . The complete PIP polynucleotide sequence was obtained from a cDNA clone encoding PIP, given by SEQ ID NO:1, along with the full amino acid sequence deduced from it. Also disclosed is a recombinant protein PIP, which shows strong lethal toxin neutralizing activity similar to the native PIP, and has potent anti-inflammatory activity. Both the native and the functionally equivalent recombinant PIP are useful for the prevention or treatment of conditions such as snakebites, insect stings, and inflammatory diseases. Also, phospholipase A 2  (PLA 2 ) inhibitory polypeptides designated P-0029, P-0009, and P-0006, the sequences of which are given as SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, respectively, are disclosed. Those polypeptides, and their synthetic chemical analogues and polypeptide variants that inhibit PLA 2  activity and alleviate inflammation, may also be used in the diagnosis, study, prevention, and treatment of PLA 2 -related human inflammatory diseases.
Patients received ETN dose 50 mg once weekly or Sulphasalazine dose 3 g daily in study 402 for 16 weeks. Upon enrollment into study 405, all received subcutaneous injections of etanercept 50 mg once weekly for 36 weeks.
Panfoshu was taken for 30 days in the first month, stopped in the second month, taken for 10 days and stopped for 20 days in a row for 3 months, and finally observed for 1 month. Usage and dosage: adults and adolescents above 12yrs take one capsule (7.0mg) every day, children (1yrs-12yrs) take one capsule (3.5mg) every day.
The present invention is related to the field of immunology, particularly the generation and selection of monoclonal antibodies (mAbs) against gangliosides (Abls) which antibodies are specific, have recurrent idiotypes and have value as immunoregulators of the immune response against those antigens, and to obtaininganti-idiotypic mAbs (Ab2s) generated by the immunization with the said anti ganglioside mAbs. Accordingly, an objective of this invention is to provide anti ganglioside mAbs (Abls) with idiotypes capable of inducing an antigen specific response (Abl') in the absence of the antigen and the methods for its generation. Another objective of this invention is to provide anti-idiotypic mAbs (Ab2s) generated by immunization with anti ganglioside mAbs that have the above mentioned property and also capable of producing all Abl' response. A further objective of the invention comprises generating specific anti ganglioside mAbs (Abl, immunizing mice and other species with said antibodies and selecting those antibodies capable of generating an antigen specific response (Abl'): generating anti-idiotypic mAbs by immunizing mice or other animal species with aforementioned anti ganglioside mAbs. It will be understood that where the term antibodies is used herein that fragments, derivatives and the like which have similar antigen grinding properties are also intended. Many ways of arriving at derivatives and/or fragments are known in the Art. Ways of producing derivatives and/or fragments include but are not limited to chemical cleavage and/or (re) assembly, recombinant production of single chain antibodies and/or molecular recognition units (MRU's), CDR-grafting class switches, etc.
Gastric cancer (GC) is the fourth-leading cause of cancer-related mortality. The intestinal subtype of GC comes after the cascade of Correa, presenting H. pylori infection as the major etiological factor. One of the main mechanisms proposed for the progression from a more benign gastric lesion to cancer is DNA damage caused by chronic inflammation. Polymorphisms in DNA repair genes can lead to an imbalance of host DNA damage and repair, contributing to the development of GC. From there, we evaluated the risk of polymorphisms in DNA repair system genes in progressive gastric diseases and their association with the H. pylori genotype. This study included 504 patients from two public hospitals in Brazil's north and northeast regions. The samples were classified into active and inactive gastritis, metaplasia, and GC. Polymorphisms in the DNA repair genes MLH1-93G > A, APE1 2197 T > G, XRCC1 28,152 G > A, MGMT 533 A > G, and XRCC3 18,067C > T were investigated by RFLP-PCR and H. pylori genotype by PCR. Statistical analyses were conducted using EPINFO 7.0., SNPSTAT, and CART software. The XRCC1 (GA) polymorphic allele stood out because it was associated with a lower risk of more severe gastric disease progression. Haplotypes of XRCC1 (GA) associated with some genotypes of MGMT, XRCC3, MLH1, and APE1 also showed protection against the progression of gastric diseases. XRCC3 (CT) showed a decreased risk of gastric disease progression in women, while a risk 1.3x to GC was observed in the MLH1 (A) polymorphic allele. The interaction between H. pylori genes and the host showed that the H. pylori cagE gene was the most important virulence factor associated with a worse clinical outcome, even overlapping with the XRCC1 polymorphism, where the MLH1 polymorphism response varied according to vacA alleles. Our results show the relevance of XRCC1 G > A for genome integrity, sex influence, and interaction between H. pylori virulence factors and XRCC1 and MLH1 genotypes for gastric lesion outcomes in Brazilian populations.
The invention relates to an application of DQ690018 or DQ690018 mimics in preparing a medicament for promoting bone mesenchymal stem cell osteogenic differentiation and bone formation. Also provided is the use of DQ690018 or DQ690018 mimics in the manufacture of a medicament for osteoporosis. The present invention uses CCK-8, clonality and EdU assays to detect the effect of piRNA DQ690018 on BMSC proliferation. Wound healing and Transwell assays were used to assess the effect of piRNA DQ690018 on BMSC migration. RNA sequencing was performed to identify DQ690018. The effect of DQ690018 on osteogenic differentiation was evaluated by alkaline phosphatase and alizarin red staining. Bone mass was measured using Micro-CT and hematoxylin-eosin staining. During the proliferation of BMSCs, 15 piRNA were up-regulated and 81 piRNA were down-regulated. DQ690018 promotes BMSC proliferation by down-regulating p21 expression and BMSC-migration by up-regulating vinca protein (Vcl) expression. In addition, it improves osteogenic differentiation of BMSCs and promotes the role of BMSC basal cell therapy in maintaining bone mass. DQ690018 is therefore a novel target for increasing BMSC proliferation, migration and osteogenic differentiation.
In the total intravenous anesthesia(TIVA) group, target controlled infusion (TCI) I was performed with propofol 4 mcg / ml. When the consciousness of the patient is lost, Remifentanil is administered as TCI with a target concentration of 1 ng / ml as an analgesic agent, and rocuronium 0.5 mg / kg is administered intravenously for intubation.
Alemtuzumab treatment was on a fixed schedule of two treatment courses a year apart for participants who received Rebif® in one of the prior Genzyme-sponsored studies of alemtuzumab or on an as needed schedule (e.g. due to documented evidence of resumed Multiple Sclerosis \[MS\] activity) for participants who had already completed a fixed schedule of treatment with alemtuzumab in one of the prior Genzyme-sponsored studies. There was no comparison treatment in this study. All participants were required to return to their study site every 3 months for neurologic and other assessments. In addition, safety-related laboratory tests and surveys were performed at least monthly. Participation in the extension study was at least 48 months from enrollment. Study duration could be extended to allow participants to remain in the study until a follow-up study was available in their country or through month 60 (month 72 in USA), whichever occurred first.
Pathological scars result from abnormal wound healing and represent a fibrotic process in the repair of skin injuries. Post-burn scars are prone to malignant transformation, especially when ulceration occurs, raising concerns for precancerous lesions. We report a case of a 56-year-old female with a 50-year history of a large burn scar on her left forearm. The scar developed non-healing ulceration with local pain and itching over the past three years. Treatment with hematoporphyrin photodynamic therapy (HpD-PDT) led to resolution of the ulceration, thinning of the scar tissue, and significant alleviation of pain and itching. After a five-year follow-up, there has been no recurrence of ulceration, suggesting that photodynamic therapy effectively promotes wound healing in scarred tissue with ulcerations.
Women diagnosed with a pelvic mass (ovarian, uterine, retroperitoneal, etc.) who are scheduled for an imaging guided biopsy, surgical biopsy or surgical excision for evaluation of their pelvic mass. Must have a pelvic imaging study performed within 60 days prior to surgery and a research blood draw within 30 days prior to surgery.
PURPOSE: A novel compound isolated from Phomopsis lingicolla ssp. and a method for preparing the same are provided to develop antibiotics and to ensure antibacterial activity. CONSTITUTION: A novel compound is denoted by chemical formula 1. The compound of chemical formula 1 is obtained by isolating culture liquid of Phomopsis lingicolla ssp. or chemically synthesized. A method for preparing the compound of chemical formula 1 or derivative thereof comprises: a step of culturing Phomopsis lingicolla ssp. and isolating spawn lump from the culture liquid; a step of adding a polar solvent to the spawn lump and filtering to obtain a crude extract; a step of extracting the crude extract with non-polar solvent and decompressing; and a step of performing gel filtration chromatography and high performance liquid chromatography. A pharmaceutical formulation contains the compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient.
INTRODUCTION: Left bundle branch area (LBBA) pacing (LBBAP) has been proposed as an alternative therapy option in patients indicated for cardiac pacing to treat bradycardia or heart failure. The aim of the study was to evaluate the safety and effectiveness of LBBAP in patients implanted with a Tendril 2088 stylet-driven lead.
METHODS: The international retrospective data collection registry included 11 sites from 5 countries globally. Patients with attempted implants of the Tendril lead in the LBBA were followed for at least 6 months post the implant attempt. The primary safety and efficacy endpoints were freedom from LBBAP lead-related serious adverse events and the composite of LBBA capture threshold of ≤2.0 V and R-wave amplitudes ≥5 mV (or ≥value at implant), respectively.
RESULTS: Of 221 patients with attempted implants of the Tendril 2088 lead in the LBBA, 91.4% (202/221) had successful implants for LBBAP. Regardless of the LBBAP implant success, all patients were followed for at least 6 months (8.7 ± 7.3 months). Baseline characteristics: 44% female, 84% ≥65 years old, 34% coronary artery disease, and 86% of primary indications for pacemaker implant. Both primary safety and effectiveness endpoints were met (freedom from LBBAP lead-related serious adverse device effects of 99.5% and electrical performance composite success rate of 93%). The capture thresholds in LBBAP at implant and 6 months were 0.8 ± 0.3 V@0.4 ± 0.1 ms and 0.8 ± 0.3 V@0.4 ± 0.1 ms. The rate of patients with capture threshold rise ≥1 V was 1.5% through 6 months. The R-wave amplitudes in LBBAP at implant and 6 months were 9.3 ± 3.2 mV and 10.6 ± 3.0 mV.
CONCLUSIONS: This large multicenter study demonstrates that the stylet-driven Tendril™ STS 2088 lead is safe and effective for LBBAP with high success and low complication rates.
Sarcoidosis is a systemic disorder of unknown cause that primarily involves the lung and lymphatic systems and that can be more reliably diagnosed if a compatible clinical picture is combined with a pathologic demonstration of non-necrotizing epithelioid-cell granulomas. As the thorax (bronchi, lung parenchyma, and/or intrathoracic lymph nodes) is almost invariably involved, bronchoscopy with its ancillary sampling procedures (endobronchial biopsy, transbronchial lung biopsy, bronchoalveolar lavage, conventional and ultrasound guided-transbronchial needle aspiration, endoscopic ultrasound with fine needle aspiration) has been the diagnostic tool most frequently used to confirm pathologically the clinical suspect of sarcoidosis.

Among the possible bronchoscopic sampling procedures, endobronchial biopsy (EBB), which is the easiest and safest, has long been used, even though its value has been assessed in small studies, mostly retrospective. Although its diagnostic yield has been shown to be widely variable (5%-71%) across different studies, EBB has constantly demonstrated to increase the diagnostic success of bronchoscopy in sarcoidosis when coupled with other sampling methods. In the last few years, high-definition (HD) videobronchoscopy has become widely available in the market and will progressively become the standard of care for airway inspection and sampling, as it provides substantially higher resolution images as compared to conventional white light bronchoscopy. Furthermore, in combination with improved video processor units, some HD videobronchoscopes offer post-processing real-time image enhancement (i-scan technology). Preliminary studies, performed in the setting of lung cancer, suggest that HD bronchoscopy with optical image enhancement (OE) may result in better detection of subtle vascular abnormalities in the airways, which are often associated with preneoplastic lesions. We hypothesize that HD videobronchoscopy could help identify bronchial involvement from sarcoidosis before it is (plainly) visible by conventional bronchoscopy.
The invention provides a group I serous group 4 avian adenovirus genetic engineering subunit vaccine, a preparation method and application thereof, belonging to the field of genetic engineering. A group I serous group 4 avian adenovirus genetic engineering subunit vaccine, the antigen of the vaccine is polypeptide with a sequence shown as SEQ ID NO. 2. The invention also provides a concatenated seedling containing the polypeptide with the sequence shown in SEQ ID NO. 2. The genetic engineering subunit vaccine has better prevention and control effects on the I group serum type 4 avian adenovirus infection.
Mothers and their low-birth weight babies will be enrolled 72 hours after birth and followed through 12 months postpartum. The prospective cohort survey (which includes anthropometric measurements and feeding observations) occurs at multiple time points over this 12-month period.
Participants will be instructed to perform 3 sessions of weight-bearing exercise per week, for 12 weeks. Exercise intensity and duration will be low-to-moderate in the first 4 weeks, and will progressively increase during the program. Participants will be supported by educational materials, a heart rate monitor, and by means of periodic contact with an exercise specialist via video and phone calls, and text messages.
The invention provides a proved prescription used for treating eczema. Eczema belongs to allergic dermatitis, is characterized by itching, is normally in symmetric distribution and has a variety of shapes. Acute eczema has the following symptoms: the skin itches and becomes red at first; then small papules and vesicles occur and are extremely itchy, and yellow water weeps when the small papules and vesicles are scratched; and yellow crust forms later. When acute eczema continuously recurs and is not healed for a long time, acute eczema is developed into chronic eczema. Chronic eczema has the following symptoms: the skin thickens, has wrinkles and weeping yellow water and is rough, uneven, slightly eroded and fairly itchy. Eczema commonly occurs on the face, arms and legs. Eczema on a scrotum is called as scrotal eczema. Eczema on a child with an age of less than 1 year, called as infantile eczema, is normally located on the cheek of the child. The proved prescription used for treating eczema is an innovative traditional Chinese medicinal prescription repeatedly researched and argued for years, concluded from clinical special research and developed on the basis of considerable healing cases of patients with eczema and repeated practice. The prescription adopts pure traditional Chinese medicines as raw materials; a decoction is extracted from the raw materials by using a traditional herbal medicine decocting method and applied on an affected part; and the prescription realizes treatment based on nosogenesis and has no toxic and side effects and a unique treatment effect.
The present application provides an anti-tumor recombinant collagen, and a preparation method and use therefor. The amino acid sequence of the recombinant collagen is shown as SEQ ID NO. 1. The present application also provides an anti-oxidation method and a method for inhibiting tumor growth. Compared with natural collagen, the recombinant collagen disclosed by the present application is small in molecular weight and easy to prepare, can be prepared and expressed in high-equal eukaryotic cells such as yeast, has good biological activity of natural collagen, and can effectively support cell adhesion, improve antioxidant damage resistance of the skin, and remarkably inhibit tumor cell proliferation; the recombinant collagen can be used in the fields of food, health care products, biomedicine, etc. The preparation method is safe, easy to amplify, low in production costs and has wide application prospects.
Various types of biological treatments, including antineoplastic treatments with antineoplastic drugs, can result in damage to the blood-forming function of the bone marrow. This damage can be reversed, at least to some degree, with an effective amount (preferably an extremely low dose) of a pharmaceutically acceptable dithiocarbamic compound, including a compound of the formula R1?R2?NCSSM or R1?R2?NCSS-SCSNR?3R?4, wherein R?1, R?2, R?3, and R?4 are the same or different aliphatic or cycloaliphatic or heterocycloaliphatic groups, unsubstituted or substituted by hydroxyl, or one of R?1 and R?2 and one of R?3 and R?4 can be H, or R?1 and R?2 or R?3 and R?4, taken together with the N atom upon which the pair of R groups is substituted, can be a 5- or 6-member N-heterocyclic ring which is aliphatic or aliphatic interrupted by a ring oxygen or second ring nitrogen, and M is H or one equivalent of a pharmaceutically acceptable cation, in which case the rest of the molecule is negatively charged. The dosage in mammals can range from about 0.001 to 30 mg/kg of body weight. For larger mammals, including humans, a typical dosage unit is less than 10 mg/kg, e.g. < 3 mg/kg. The dosage unit can be dissolved in a suitable pharmaceutically acceptable carrier (e.g. and aqueous medium) and is then preferably administered intravenously within 8 hours of the administration of the agent which can cause bone marrow damage. The extremely low dosages particularly preferred in this invention do not cause any significant side effects.